Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis

BACKGROUND: Siponimod (BAF312) is a selective sphingosine-1-phosphate receptor 1 and 5 (S1PR1, S1PR5) modulator recently approved for active secondary progressive multiple sclerosis (SPMS). The immunomodulatory effects of siponimod in SPMS have not been previously described. METHODS: We conducted a...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:JCI Insight
Huvudupphovsmän: Wu, Qi, Mills, Elizabeth A., Wang, Qin, Dowling, Catherine A., Fisher, Caitlyn, Kirch, Britany, Lundy, Steven K., Fox, David A., Mao-Draayer, Yang
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society for Clinical Investigation 2020
Ämnen:
Clinical Medicine
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7098784/
https://ncbi.nlm.nih.gov/pubmed/31935197
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.134251
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk